eligibility_summary
Eligible: DLBCL at Moffitt, axi-cel CAR T-eligible, ECOG 0-2, >=1 high-risk lesion >=5 cm targetable, able to receive comprehensive bridging RT to all disease, no CNS lymphoma, adequate marrow/organ function, consent, and effective contraception (or non-childbearing). Exclude: investigational therapy <=4 wks, prior CAR T, unable to deliver RT, major cardiac/unstable arrhythmia, active infection, HIV+, active HBV/HCV unless suppressed/cleared, chronic steroids, noncompliance, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in high-risk relapsed/refractory large B-cell lymphoma with bulky disease tests: 1) Comprehensive Ablative Bridging Irradiation (CABI), an external-beam ablative radiation to all feasible lesions to induce DNA damage–mediated cytotoxicity, debulk tumor, and potentially enhance subsequent immunotherapy, 2) Axicabtagene ciloleucel (axi-cel, Yescarta), an autologous anti-CD19 chimeric antigen receptor T-cell therapy (second-generation CAR with CD28 costimulation) given after lymphodepleting chemotherapy to promote CAR-T expansion. Targets: malignant CD19-positive B cells, CAR-driven T-cell cytotoxic signaling (CD3ζ/CD28), radiation targets tumor cells across all involved sites, lymphodepletion transiently reduces host lymphocytes/cytokine sinks to support CAR-T engraftment.